Peijia Medical Says B. Braun's Intracranial Drug-Coated Balloon Gets China Approval

MT Newswires Live

59 mins ago

Peijia Medical (HKG:9996) said B. Braun Medical (Suzhou)'s SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter has received approval from China's National Medical Products Administration.

The device is designed to treat narrowed intracranial blood vessels using a paclitaxel drug-coated balloon, without leaving an implant in the vessel, according to a Friday filing on Hong Kong bourse.

Peijia Medical unit Shanghai Achieva Medical Suzhou holds exclusive distribution rights for SeQuent Please CIS in mainland China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2670844474"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2670844474\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2670844474?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-25 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2670844474","market":"nz","top_or_hot":-1,"title":"Peijia Medical Says B. Braun's Intracranial Drug-Coated Balloon Gets China Approval","media":"MT Newswires Live","content":"<html><body><p> Peijia Medical (HKG:9996) said B. Braun Medical (Suzhou)'s SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter has received approval from China's National Medical Products Administration.</p><p>The device is designed to treat narrowed intracranial blood vessels using a paclitaxel drug-coated balloon, without leaving an implant in the vessel, according to a Friday filing on Hong Kong bourse.</p><p>Peijia Medical unit Shanghai Achieva Medical Suzhou holds exclusive distribution rights for SeQuent Please CIS in mainland China.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Peijia Medical Says B. Braun's Intracranial Drug-Coated Balloon Gets China Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPeijia Medical Says B. Braun's Intracranial Drug-Coated Balloon Gets China Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-25 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Peijia Medical (HKG:9996) said B. Braun Medical (Suzhou)'s SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter has received approval from China's National Medical Products Administration.</p><p>The device is designed to treat narrowed intracranial blood vessels using a paclitaxel drug-coated balloon, without leaving an implant in the vessel, according to a Friday filing on Hong Kong bourse.</p><p>Peijia Medical unit Shanghai Achieva Medical Suzhou holds exclusive distribution rights for SeQuent Please CIS in mainland China.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2670844474","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2670844474","pubTimestamp":1790333891,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Peijia Medical  said B. Braun Medical 's SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter has received approval from China's National Medical Products Administration.The device is designed to treat narrowed intracranial blood vessels using a paclitaxel drug-coated balloon, without leaving an implant in the vessel, according to a Friday filing on Hong Kong bourse.Peijia Medical unit Shanghai Achieva Medical Suzhou holds exclusive distribution rights for SeQuent Please CIS in mainland China.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1100":"医疗保健设备","09996":"沛嘉医疗-B","BK1574":"生物医药B类股"},"translate_title":"培佳医疗称博朗颅内药物涂层球囊获得中国批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09996":1},"content_text":"Peijia Medical (HKG:9996) said B. Braun Medical (Suzhou)'s SeQuent Please CIS paclitaxel drug-coated intracranial balloon dilatation catheter has received approval from China's National Medical Products Administration.The device is designed to treat narrowed intracranial blood vessels using a paclitaxel drug-coated balloon, without leaving an implant in the vessel, according to a Friday filing on Hong Kong bourse.Peijia Medical unit Shanghai Achieva Medical Suzhou holds exclusive distribution rights for SeQuent Please CIS in mainland China.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}